Your browser doesn't support javascript.
loading
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
O'Malley, David M; Oza, Amit M; Lorusso, Domenica; Aghajanian, Carol; Oaknin, Ana; Dean, Andrew; Colombo, Nicoletta; Weberpals, Johanne I; Clamp, Andrew R; Scambia, Giovanni; Leary, Alexandra; Holloway, Robert W; Gancedo, Margarita Amenedo; Fong, Peter C; Goh, Jeffrey C; Swisher, Elizabeth M; Maloney, Lara; Goble, Sandra; Lin, Kevin K; Kwan, Tanya; Ledermann, Jonathan A; Coleman, Robert L.
Afiliação
  • O'Malley DM; Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH, USA. Electronic address: David.O'Malley@osumc.edu.
  • Oza AM; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Lorusso D; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Aghajanian C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Oaknin A; Gynecologic Cancer Program, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Dean A; Department of Medical Oncology, St John of God Subiaco Hospital, Subaico, WA, Australia.
  • Colombo N; Department of Gynecologic Oncology, University of Milan-Bicocca and European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Weberpals JI; Department of Obstetrics and Gynecology, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Clamp AR; Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
  • Scambia G; Department of Cancer Gynecology, Fondazione Policlinico Universitario A. Gemelli IRCCS and Scientific Directorate, Rome, Italy.
  • Leary A; Gynecological Unit, Gustave Roussy Cancer Center, INSERM U981, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, France.
  • Holloway RW; Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando, FL, USA.
  • Gancedo MA; Medical Oncology Department, Oncology Center of Galicia, La Coruña, Spain.
  • Fong PC; Medical Oncology, Auckland City Hospital and University of Auckland, New Zealand.
  • Goh JC; Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Australia; Faculty of Medicine, University of Queensland, St Lucia, Australia.
  • Swisher EM; Division of Gynecologic Oncology, University of Washington, Seattle, WA, USA.
  • Maloney L; Clinical Development, Clovis Oncology, Inc., Boulder, CO, USA.
  • Goble S; Biostatistics, Clovis Oncology, Inc., Boulder, CO, USA.
  • Lin KK; Molecular Diagnostics, Clovis Oncology, Inc., Boulder, CO, USA.
  • Kwan T; Molecular Diagnostics, Clovis Oncology, Inc., Boulder, CO, USA.
  • Ledermann JA; Department of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, UK.
  • Coleman RL; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gynecol Oncol ; 167(3): 404-413, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36273926
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article